AVLSA
JBIO

Atlas Venture Life Science Advisors’s Jade Biosciences JBIO Stock Holding History

Atlas Venture Life Science Advisors’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-51,407
Closed -$4.52M – 12
2025
Q1 		$4.52M Hold
51,407
– – 0.87% 10
2024
Q4 		$4.77M Hold
51,407
– – 0.58% 11
2024
Q3 		$3.76M Hold
51,407
– – 0.35% 12
2024
Q2 		$2.99M Sell
51,407
-6,857
-12% -$4.55M 0.31% 14
2024
Q1 		$60.3M Hold
58,264
– – 5.57% 7
2023
Q4 		$46.1M Hold
58,264
– – 5.5% 7
2023
Q3 		$27.7M Hold
58,264
– – 4.29% 9
2023
Q2 		$35M Hold
58,264
– – 4.35% 9
2023
Q1 		$41.1M Buy
58,264
+621
+1% +$515K 5.57% 7
2022
Q4 		$59.1M Sell
57,643
-8,869
-13% -$6.44M 7.12% 6
2022
Q3 		$38.6M Sell
66,512
-8,868
-12% -$5.92M 4.26% 8
2022
Q2 		$41.2M Sell
75,380
-13,302
-15% -$6.35M 6.89% 6
2022
Q1 		$56.9M Hold
88,682
– – 7.19% 5
2021
Q4 		$36.6M Buy
+88,682
New +$44.9M 3.36% 9

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Atlas Venture Life Science Advisors's JBIO Position: Q2 2025 in Review

Atlas Venture Life Science Advisors sold out of Jade Biosciences (JBIO) in Q2 2025, closing a stake of 51,407 shares — an estimated $4.52M sold.

Atlas Venture Life Science Advisors first reported a position in JBIO in Q4 2021 and held it in 14 quarters. The position peaked at $60.3M in Q1 2024. 75 funds tracked by Wall St. Rank hold JBIO as of Q2 2025.

  • Atlas Venture Life Science Advisors reported no remaining Jade Biosciences position as of Q2 2025 after selling out during the quarter.
  • Atlas Venture Life Science Advisors sold 51,407 Jade Biosciences shares in Q2 2025, an estimated $4.52M.
  • Atlas Venture Life Science Advisors first reported a position in Jade Biosciences in Q4 2021 and held it in 14 quarters.
  • Atlas Venture Life Science Advisors's Jade Biosciences position peaked at $60.3M in Q1 2024.
  • 75 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2025.

Based on Atlas Venture Life Science Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.